Core Viewpoint - Sunshine Nuohuo has announced a significant asset restructuring plan to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd, aiming to enhance its capabilities in the pharmaceutical industry through resource integration and strengthen its full-chain layout for sustainable development [1][2]. Group 1: Acquisition Details - The acquisition will be executed through the issuance of shares and convertible bonds, focusing on integrating high-difficulty generic drug and innovative drug research, production, and sales [1]. - Langyan Life is a comprehensive pharmaceutical enterprise with established production capacity and channel resources in high-end chemical drugs and raw materials, covering critical clinical areas such as cardiovascular and anti-infection [1]. Group 2: Strategic Synergy - The collaboration between Sunshine Nuohuo's R&D strengths and Langyan Life's production capabilities is expected to create a synergistic effect, accelerating the technological upgrade of existing production capacity and providing a conversion platform for self-researched pipelines [2]. - Sunshine Nuohuo's innovative drug projects can quickly transition from laboratory to market using Langyan Life's production lines, while Langyan Life's mature products can benefit from Sunshine Nuohuo's R&D resources for process optimization and new indication development [2]. Group 3: Industry Context - The acquisition is positioned as a response to increasing policy changes in the pharmaceutical industry, which have heightened the need for industry chain division and integration [2]. - By pursuing vertical integration, Sunshine Nuohuo aims to enhance cost control across R&D, production, and sales, reducing reliance on external capacity and improving risk resilience amid the normalization of centralized procurement [2]. Group 4: Strategic Upgrade - This acquisition is a key move in Sunshine Nuohuo's strategic upgrade, reinforcing its "CRO + innovative R&D + pharmaceutical industry" layout, maintaining the professionalism of R&D services while enhancing the effectiveness of industrial transformation [3]. - The ongoing integration is expected to become a crucial support for optimizing the company's revenue structure [3].

中国医药公告称，公司拟以现金3.02亿元收购中国新兴集团有限责任公司（以下简称新兴集团）所持北 京金穗科技开发有限责任公司（以下简称金穗科技）100%股权。新兴集团系公司控股股东通用技术集 团的全资子公司，此次交易构成关联交易。金穗科技主营业务为电商运营服务，目前的核心业务为飞利 浦个人健康消费等产品的品牌授权经销。 阳光诺和：拟购买朗研生命100%股权 每经记者｜范芊芊 每经编辑｜张海妮 并购重组 中国医药：拟3.02亿元收购金穗科技100%股权 中铁工业：控股股东中国中铁拟1.6亿元至3亿元增持公司股份 阳光诺和公告称，公司拟通过发行股份及可转换公司债券方式，购买利虔、朗颐投资等38名股东持有的 江苏朗研生命科技控股有限公司（以下简称朗研生命）100%股权，并向不超过35名特定投资者发行股 份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外提供药品生产服 务。 云南铜业：筹划购买凉山矿业40%股份 云南铜业公告称，正在筹划发行股份购买云南铜业（集团）有限公司（以下简称云铜集团）持有的凉山 矿业股份有限公司（以下简称凉山矿业）40%股份并募集配套资金。因有关事项尚存在不确定性，公司 ...